PARIS--(BUSINESS WIRE)--Regulatory News: Acticor Biotech (Paris:ALACT), a clinical stage biotechnology company developing an innovative drug for the treatment of cardiovascular emergencies, today ...

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies, today ...

Four drug companies — Agomab Therapeutics, Eikon Therapeutics, Spyglass Pharma, and Veradermics — went public this week, ...

Biomedicines is the latest biotech to mull going public as momentum for IPOs continues to build. | Clinical-stage antibody company Generate:Biomedicines is the latest biotech to mull going public as ...

The FDA approval of Biogen's Alzheimer's disease drug Aduhelm was the biggest surprise. Several COVID-19 vaccine stocks skyrocketed well beyond expectations. Relatively few mergers and acquisitions ...

Insider got exclusive data on the highest-paid CEOs in the pharma and biotech industries in 2021. The research firm MyLogIQ identified 15 CEOs that made at least $25 million last year. These leaders ...

Over the past two calendar years, acquirers have agreed to pay more than $38 billion to purchase venture-backed companies in ...

If you look at a stock chart mapping the performance of the State Street SPDR S&P Biotech exchange-traded fund since early 2021, it seems to tell a simple story: The biotech sector has been a disaster ...

Welcome to The TechCrunch Exchange, a weekly startups-and-markets newsletter. It’s inspired by the daily TechCrunch+ column where it gets its name. Want it in your inbox every Saturday? Sign up here.

Whisper it, but we may finally be seeing the IPO window reopening in 2026. | Whisper it, but we may finally be seeing the IPO window reopening in 2026.

From top left, clockwise: Fred Hutch’s Hilary Hehman; Oregon Venture Fund’s Eric Rosenfeld; Alexandria’s Alice Ly; University of Washington’s François Baneyx; sp3nw’s Michaele Armstrong; and ...